Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 intraperitoneal GPC3-CAR iPSC-derived ILC/NK therapy in ovarian clear cell carcinoma
jRCT2033200431Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2021
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iCAR-ILC-N101 in clear cell ovarian cancer and peritoneal carcinomatosis (PC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety and dose-limiting toxicity of iCAR-ILC-N101. Started May 2021; status: recruiting.
02
Drugs
iCAR-ILC-N101
03
Conditions
clear cell ovarian cancerperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on jRCT2033200431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033200431.